Bayer: new data for menopause treatment

(CercleFinance.com) - Bayer will unveil new data from its long-term Phase III OASIS 3 study of elinzanetant in the treatment of vasomotor symptoms associated with menopause.


Detailed results from the Phase III OASIS 3 study evaluating the long-term efficacy and safety of the investigational compound elinzanetant will be presented for the first time at this year's annual meeting of the Menopause Society (TMS), to be held 10-14 September in Chicago, Illinois, US.

Elinzanetant is the first dual neurokinin-1 and 3 (NK-1 and 3) receptor antagonist being investigated for the non-hormonal treatment of moderate to severe menopause-associated VMS, administered orally once daily.

Following the positive results of the OASIS 1, 2 and 3 studies, Bayer has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for elinzanetant in the treatment of moderate to severe menopausal VMS. Bayer will also submit marketing authorization applications for elinzanetant to other health authorities.


Copyright (c) 2024 CercleFinance.com. All rights reserved.